ArticleInflammopharmacology2026
Mechanistic insights into the anti-inflammatory effects of isocoronarin D associated with reduced PKCδ and PI3K/Akt signalling in LPS-activated macrophages.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Curcuma comosa Roxb., a Thai medicinal plant, has long been used to relieve postmenopausal symptoms and is known to exhibit anti-inflammatory properties. Isocoronarin D, a labdane diterpene and the main bioactive compound in the aerial parts of C. comosa, has previously been reported to induce foetal haemoglobin synthesis. However, its anti-inflammatory activity, predicted molecular targets, pharmacokinetic characteristics, and toxicity remain insufficiently characterised. Therefore, this study integrates in silico predictions of its molecular targets, pharmacokinetic behaviour and toxicity with in vitro validation of its anti-inflammatory effects and underlying mechanisms to address these knowledge gaps. Initially, network pharmacology analysis identified protein kinase Cδ (PKCδ), phosphoinositide 3-kinase (PI3K), and cyclooxygenase-2 (COX-2) as inflammation-related targets computationally associated with isocoronarin D. These predicted targets were subsequently validated in vitro, where isocoronarin D significantly reduced the production of inflammatory mediators, including inducible nitric oxide synthase (iNOS), COX-2, tumour necrosis factor-α, interleukin (IL)-1β, and IL-6, in lipopolysaccharide (LPS)-activated RAW264.7 macrophages. Moreover, isocoronarin D inhibited the phosphorylation of PKCδ, PI3K, and Akt, indicating suppression of key inflammatory signalling pathways. The observed inhibition of these inflammatory proteins, together with the predicted interactions revealed by molecular docking, supports a mechanistically relevant role for these proteins as inflammatory targets of isocoronarin D. In addition, in silico SwissADME, pkCSM, and GUSAR analyses suggested drug-like characteristics, favourable pharmacokinetic properties, and a non-toxic safety profile. Collectively, these findings indicate that isocoronarin D exerts multi-target anti-inflammatory activity and warrants further in vivo investigation to better elucidate its therapeutic relevance in inflammation-related diseases.
Indexed as
Identifiers
41680540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.